6-08-2025, 18:00

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Notified -
Globe Newswire6-08-2025, 18:00
7-04-2025, 18:30

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Notified -
Globe Newswire7-04-2025, 18:30
4-12-2024, 14:00

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Notified -
Globe Newswire4-12-2024, 14:00